Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 4;113(16):4476–4481. doi: 10.1073/pnas.1525360113

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Freely available online through the PNAS open access option.

PMC Copyright notice

Fig. 4. — In the Gl261 model treatment with A2V shifts TAMS toward the M1 state. In all panels, IgG, n = 6; B20, n = 6; A2V, n = 5. (A and B) Gating through CD45^high/CD11b⁺ and F4/80⁺/GR1⁻ identified macrophages. (C) Treatment with A2V or B20 did not lead to significant changes in the total percentage (percent of all CD45^pos cells) of Gl261 tumor-infiltrating macrophages compared with IgG control. (D) The percentage of CD206^low/CD11c^high M1-polarized macrophages (as a percentage of total macrophages) was increased in A2V-treated Gl261 tumors as compared with IgG-treated tumors (*P = 0.02). (E) CD206^high/CD11c^low M2 macrophages were decreased by A2V treatment compared with IgG treatment (**P = 0.004). B20 therapy decreased M2 macrophages compared with IgG therapy (**P = 0.01). (F) The M1/M2 ratio showed a trend toward the M1 polarization state in A2V-treated animals compared with IgG-treated animals. (G–I) Representative gates for IgG (G), B20 (H), and A2V (I) to identify M1 and M2 macrophages.